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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of quetiapine dosage for people with schizophrenia and schizophrenia-related disorders.
B A C K G R O U N D
Description of the condition
Schizophrenia is a severe and enduring mental illness charac-
terised by distortions in perception and cognition. Symptoms of
schizophrenia can be categorised into two main groups of pos-
itive and negative symptoms (WHO 1994; APA 2013). Posi-
tive symptoms signify changes in thought or behaviour, or both,
which include fixed, false beliefs (delusions), perceptions without
cause (hallucinations), thought insertion or withdrawal, thought
broadcasting, bizarre posturing and behaviours such as catatonia
(Carpenter 1994; Blows 2010). Negative symptoms represent ap-
athy or lack of motivation (avolition), lack of pleasure (anhedo-
nia), blunting of affect, declining in social functioning, disorgan-
isation of behaviour and thought (Carpenter 1994; Blows 2010;
Kuipers 2014). For a person to be diagnosed with schizophrenia
they must exhibit at least both positive and negative symptoms
for six months, with at least one symptom active during the prior
month (APA 2013). More recently, International Classification
of Diseases 11th Revision (ICD-11) has updated the schizophre-
nia definition; however the core symptoms remain similar (WHO
2018).
The course of schizophrenia is unpredictable and varies from par-
tial to full remission, continuous or episodic with progressive or
stable deficits (ICD-10) (WHO 1994). Only one in six people who
experience a psychotic episode recover fully and approximately
50% of people with a severe mental illness, such as schizophrenia,
are treatment-resistant (Marwaha 2004). The effect of schizophre-
nia can precipitate an increased risk of suicide (Tsuang 1978; Hor
2010), with an estimated suicide rate of 10% (Palmer 2005; Hor
2010). People who live with this chronic illness also experience
frequent hospitalisation, deprivation of liberty, high rates of re-
lapse, financial problems, legal difficulties, stigma, isolation and
comorbid medical conditions (Pankey 2003; Harrison 2010). Peo-
ple with schizophrenia are more likely to be single and around
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80% to 90% are unemployed (Marwaha 2004; Messias 2007).
The World Health Organization (WHO) estimates that
schizophrenia affects more than 23 million people worldwide and
commonly starts earlier in males (WHO 2003; WHO Factsheet
2018). Schizophrenia affects about 7 in 1000 adults, with first
episode onset typically occurring between the ages of 15 to 35 years
(Kuipers 2014). The point prevalence averages approximately 4.5
per population of 1000, and the risk of developing the illness
over one’s lifetime averages 0.7% (Tandon 2008). A recent sys-
tematic review estimated schizophrenia costs the global economy
between USD 94 million to USD 102 billion per annum (Chong
2014). Schizophrenia is associated with considerable disability
and may affect educational and occupational performance (WHO
Factsheet 2018). People with schizophrenia have a mortality rate
two to three times that of the general population; with men dying
20 years and women 15 years earlier than those who do not have
schizophrenia (Saha 2007; Brown 2010; Kuipers 2014).
Description of the intervention
The mainstay treatment for schizophrenia is antipsychotic med-
ication. Quetiapine is an antipsychotic used in the treatment of
schizophrenia, bipolar affective disorder and major depression.
It has been shown to be effective in the treatment of people
with schizophrenia with similar efficacy to other antipsychotics
(Srisurrapanont 2004); the only exception is clozapine which has
superiority over other antipsychotics (Kane 1988; Essali 2009).
After administration, quetiapine is rapidly absorbed with a peak
plasma concentration reached around 1 to 1.8 hours with a half-
life (T½) of around 7 hours (Markowitz 1999). Steady-state peak
concentrations of the active metabolite norquetiapine are 35% of
that observed for quetiapine. Bioavailability is not significantly
affected by the administration of food (DeVane 2001). Quetiapine
is approximately 83% bound to plasma proteins. Its main route
of metabolism is predominantly by the hepatic enzyme CYP3A4
with minor metabolism through CYP2D6; its mean elimination
half-life is approximately 6 hours (DeVane 2001), with less than
5% of the drug excreted unchanged (Markowitz 1999).
The most common side effects associated with quetiapine are
sedation, dizziness, headache, dry mouth, metabolic side effects
(changes in blood lipids and weight gain), constipation and dizzi-
ness; other side effects include extrapyramidal side effects (stiff-
ness, tremors, abnormal movements and restlessness), decreases in
blood haemoglobin levels, increased heart rate, blurred vision and
peripheral oedema (Calabrese 2005; EMC 2018).
For the treatment of schizophrenia, quetiapine is usually adminis-
tered twice a day orally. The usual effective dose range is 300 mg/
day to 450 mg/day. However, depending on the clinical response
and tolerability of the individual patient, the dose may be adjusted
within the range 150 mg/day to 750 mg/day (BNF 2018; EMC
2018).
How the intervention might work
Quetiapine, an atypical dibenzothiazepine antipsychotic has an-
tagonist properties at 5 hydroxytryptamine 2A (5HT2A) receptors
and dopaminergic D2 receptors with a higher affinity for 5-HT2A
than for D2 receptors (Tasman 2008). The stronger 5HT2A an-
tagonism increases dopaminergic neurotransmission in the nigros-
triatal pathways, hence leading to less extrapyramidal side effects
and theoretically improving negative symptoms in schizophrenia
by increasing the release of dopamine or acetylcholine, or both,
in the prefrontal cortex (Miyamoto 2012). It is a partial agonist
at 5-HT1A receptors. The blockade of 5-HT2 receptors and the
induction of brain-derived neurotrophic factor (BDNF) are the
pivotal characters of atypical antipsychotic medications and the
stimulation of 5-HT1A receptors sometimes contributes to ‘atyp-
icality’ (Kusum 2015). It is also antagonist at histamine H1 and
adrenergic alpha 1 receptors.
Quetiapine might exert its antipsychotic effects by the “kiss and
run” mechanism proposed by Kapur 2000, where quetiapine has a
rapid dissociation from D2 receptors (Kapur 2000; Kapur 2001;
Schatzberg 2009). A review by Seeman 2002 shows that quetiap-
ine and other newer, second generation, antipsychotic drugs help
clinically by binding more loosely than dopamine to the D2 re-
ceptors and dissociate rapidly to allow normal dopamine neuro-
transmission.
Studies have also demonstrated protective effects of quetiapine
and other atypical antipsychotic drugs on apoptosis with neuronal
cell culture (Gil-ad 2001; Qing 2003). This points towards a po-
tentially different mechanism of action of atypical antipsychotic
drugs.
In people with acute schizophrenia, Small 1997 found a positive
correlation between the dose of quetiapine and reduction in Brief
Psychiatric Rating Scale (BPRS; an instrument to assess symptoms
of psychosis) scores in comparison with placebo, as did Arvanitis
1997 across four fixed doses of immediate release quetiapine (150
mg, 300 mg, 600 mg, or 750 mg daily) with no significant dif-
ferences in extrapyramidal side effects. Buckley 2004’s analysis of
three double-blinded randomised controlled trials (RCTs) found
that quetiapine is effective across both domains of positive and
negative symptoms of schizophrenia, including depression and ag-
itation. Srisurrapanont 2004 established that quetiapine showed
slight improvement on positive and negative symptoms, as mea-
sured by mental states using BPRS and Positive and Negative Syn-
drome Scale (PANSS). Srisurrapanont 2004 posited there are little
to no data on the effects of quetiapine on social functioning and
quality of life.
Why it is important to do this review
Most people diagnosed with schizophrenia require both antipsy-
chotic treatment and additional psychosocial support with con-
tinued follow-up. The cost of continued care is expensive but rela-
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tively small compared to the advantages of enhanced quality of life
and functionality (WHO 2003). Undertaking risk-benefit analy-
ses and finding effective evidence-based treatments is vital.
Quetiapine is an effective antipsychotic for people with
schizophrenia (Srisurrapanont 2004), but uncertainties prevail
about quetiapine dosage. Results from a meta-analysis concern-
ing high-dose (750 mg/day to 800 mg/day) versus low-dose (300
mg/day to 400 mg/day) quetiapine in terms of the response rate,
changes in positive symptoms and discontinuation rate (due to
either adverse effects or no response) showed no statistically signif-
icant difference amid both categories of treatment (high- and low-
dose quetiapine) (Citrome 2005; Painuly 2010). Sparshatt 2008
and Buckley 2004 found similar results. On the other hand, Kahn
2007, found a statistically significant correlation between increas-
ing the dose and a positive therapeutic effect.
The choice of the dose of quetiapine is guided by the risk-bene-
fit analysis. Common side effects of quetiapine include sedation,
dizziness, asthenia (lack of energy) and dry mouth but, in com-
parison with other antipsychotics such as haloperidol and chlor-
promazine, quetiapine has lower association with extra-pyramidal
side effects (Srisurrapanont 2004). Dose-related side effects, es-
pecially the risk of cardiac-sudden death (Ray 2009), remains a
limiting factor in abiding by guidelines that supports high dose
for an enhanced response. Dose of quetiapine in clinical practice
is influenced by factors, such as length of stay in hospital and prior
hospitalisation. However, there is no clear evidence to guide the
practice of using high dosage in such cases (Citrome 2005).
According to Srisurrapanont 2004, the usual clinical practice has
not been explored in depth. It is important to clarify what dose of
quetiapine should be prescribed under what circumstances and at
which particular phase of illness. For instance, in acute phase, the
quetiapine dose range used is higher than that in the maintenance
phase as with other antipsychotic drugs; however, this range dif-
fers between studies (McCue 2006; McEvoy 2006; Riedel 2007;
Sparshatt 2008).
This Cochrane Review aims to provide clarity about the effects
of quetiapine dose range for people with schizophrenia, including
different preparations, by assessing evidence available from RCTs.
O B J E C T I V E S
To assess the effects of quetiapine dosage for people with
schizophrenia and schizophrenia-related disorders.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include RCTs that meet the inclusion criteria and re-
port useable data. We will exclude quasi-randomised studies, such
as those that allocate intervention by alternate days of the week.
Where people are given additional treatments as well as quetiap-
ine, we will only include data if the adjunct treatment is evenly
distributed between groups and only treatment with quetiapine is
randomised.
Types of participants
Adults (aged 16 years and older) with schizophrenia or related dis-
orders, including schizophreniform disorder, schizoaffective disor-
der and delusional disorder (diagnosed using a standardised crite-
ria (e.g.International Classification of Diseases (ICD), Diagnositc
and Statistical Manual of Mental Disorders (DSM) or by a psy-
chiatrist). We will also include trials in which participants have a
range of diagnoses, provided most participants (over 50%) have a
diagnosis of schizophrenia or related disorder.
We wish to ensure the information is as relevant as possible to the
current care of people with schizophrenia. We aim to highlight the
current clinical state clearly (acute, early post-acute, partial remis-
sion, remission), the stage (prodromal, first episode, early illness,
persistent), and whether the studies primarily focused on people
with particular problems (e.g. negative symptoms, treatment-re-
sistant illnesses).
Types of interventions
1. Quetiapine dose: oral immediate release, oral modified
release
1.1 Low: less than 300 mg daily
1.2 Medium: 300 mg to 600 mg (usual dose) daily
1.3 High: more than 600 mg daily (for both immediate release
and modified release preparations)
2. Placebo
3. Other antipsychotic medication: any dose
Types of outcome measures
We aim to divide all outcomes into short-term (less than 6 weeks),
medium-term (6 weeks to 6 months) and long-term (more than
6 months).
We will endeavour to report binary outcomes recording clear and
clinically meaningful degrees of change (e.g. global impression of
much improved, or more than 50% improvement on a valid rating
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scale - as defined within the trials) before any others. Thereafter we
will list other binary outcomes and then those that are continuous.
For outcomes such as ‘clinically important change’, ‘any change’,
and ‘relapse’, we will use the definition used by the trial authors.




1.1 Clinically important change in global state
2. Quality of life





1.1 Any change in global state
1.2 Average endpoint or change score on a global state scale
2. Quality of life
2.1 Any change in quality of life
2.2 Average endpoint score on quality of life scale
3. Adverse effects
3.1 General
3.1.1 At least one clinically important adverse effect/event
3.1.2 Average endpoint or change score on adverse effect scale
3.2 Specific effects
3.2.1 Extrapyramidal side effects
3.2.2 Metabolic effects
3.2.3 Cardiovascular effects
3.2.4 Various other effects
3.3 Death: suicide or any cause.
4. Mental state
4.1 General
4.1.1 Clinically important change in general mental state
4.1.2 Any change in general mental state
4.1.3 Average endpoint or change score on a general mental state
scale
4.2 Specific symptoms (e.g. positive, negative, affective)
4.2.1 Clinically important change in specific symptoms
4.2.2 Any change in specific symptoms




5.1.1 Clinically important change in general functioning
5.1.2 Any change in general functioning
5.1.3 Average endpoint or change score on general functioning
scale
5.2 Social or life skills
5.2.1 Clinically important change in social functioning or life skills
5.2.2 Any change in social functioning or life skills
5.2.3 Average endpoint or change score on social functioning or
life skills scale
6. Leaving the study early
6.1 For any reason
6.2 For specific reason
7. Service use
7.1 Hospital admission
7.2 Time in hospital
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‘Summary of findings’ table
We will use the GRADE approach to interpret findings (
Schünemann 2011). To create a ‘Summary of findings’ table we
will use GRADEpro GDT 2015 to export data from the Review
Manager file (Review Manager 2014). These tables provide out-
come-specific information concerning the overall certainty of evi-
dence from each included study in the comparison, the magnitude
of effect of the interventions examined, and the sum of available
data on all outcomes we rate as important to patient care and de-
cision making. We aim to select the following clinically important
outcomes for inclusion in the ‘Summary of findings’ table:
1. Global state: clinically important change in global state
2. Quality of life: clinically important change in quality of life
3. Adverse effects: sedation
4. Mental state: clinically important change in general mental
state
5. Leaving the study early: for any reason
6. Leaving the study early: for specific reason
7. Service use: hospital admission
If data are unavailable for these pre-specified outcomes but are
available for ones that are similar, we will present the closest out-
come to the pre-specified one in the table. However, we will take
this into account when assessing the certainty of the evidence for
the finding.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Study-Based Register of
Trials
The Information Specialist of the Cochrane Schizophrenia Group
will search the register using the following search strategy:
(*Quetiapine* AND *Dosage*) in Intervention Field of STUDY
In this study-based register, searching the major concept retrieves
all the synonyms and relevant studies because all the studies have
already been organised based on their interventions and linked to
the relevant topics (Shokraneh 2017; Shokraneh 2018).
This register is compiled by systematic searches of major re-
sources (AMED, BIOSIS, CENTRAL, CINAHL, ClinicalTri-
als.gov, Embase, MEDLINE, PsycINFO, PubMed, the World
Health Organization International Clinical Trial Registry Plat-
form (WHO ICTRP)) and their monthly updates, ProQuest Dis-
sertations and Theses A&I and its quarterly update, Chinese
databases (CBM, CNKI, and Wanfang) and their annual up-
dates, handsearches, grey literature and conference proceedings
(see the Cochrane Schizophrenia Group’s website for further infor-
mation: http://schizophrenia.cochrane.org/register-trials). There
are no language, date, document type or publication status limi-
tations for inclusion of records into the register.
Searching other resources
1. Reference searching
We will inspect references of all included studies for further rele-
vant studies.
2. Personal contact
We will contact the first author of each included study for infor-
mation regarding unpublished trials. We will note the outcome of
this contact in the ‘Included studies’ or ‘Studies awaiting classifi-
cation’ tables.
Data collection and analysis
Selection of studies
For this Cochrane Review, review authors CC and YI will exam-
ine the search results by title, and will obtain all potentially rele-
vant abstracts for assessment. We will classify the articles as either
included, excluded or ‘with information missing’. Review author
MW will independently re-inspect a random 20% sample to en-
sure reliability. Where disputes arise, we will acquire the full-text
report for more detailed scrutiny. Review authors CC and YI will
obtain and independently inspect the full-text articles that poten-
tially meet the inclusion criteria. Review author MW will inspect
a random 20% of these full-text reports in order to ensure reliable
selection. Where it is not possible to resolve disagreement by dis-
cussion, we will attempt to contact the study authors for clarifi-
cation. We will list studies excluded after full-text assessment and
the reasons for exclusion in a ‘Characteristics of excluded studies’
table. We will illustrate the study selection process in a PRISMA
diagram.
Data extraction and management
1. Extraction
Review authors YI, CC and HE will extract data from all included
studies. In addition, to ensure reliability, and review author MW
will independently extract data from a random sample of these
studies, comprising 10% of the total. We will attempt to extract
data presented only in graphs and figures whenever possible, but
will include only if two review authors independently obtain the
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same result. If studies are multicentre, where possible we will ex-
tract data relevant to each. We will discuss any disagreement and
document our decisions. If necessary, we will attempt to contact
study authors through an open-ended request in order to obtain
missing information or for clarification. Review authors YI and
HE will help clarify issues regarding any remaining problems and
we will document these final decisions.
2. Management
2.1 Forms
We will extract data onto standard, pre-designed data extraction
forms.
2.2 Scale-derived data
We will include continuous data from rating scales only if:
1. the psychometric properties of the measuring instrument
have been described in a peer-reviewed journal (Marshall 2000);
2. the measuring instrument has not been written or modified
by one of the trial authors for that particular trial; and
3. the instrument should be a global assessment of an area of
functioning and not subscores which are not, in themselves,
validated or shown to be reliable. However there are exceptions,
we will include subscores from mental state scales measuring
positive and negative symptoms of schizophrenia.
Ideally the measuring instrument should either be i. a self-report
or ii. completed by an independent rater or relative (not the thera-
pist). We realise that this is not often reported clearly; in ‘Descrip-
tion of studies’ we will note if this is the case or not.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data: change
data can remove a component of between-person variability from
the analysis; however, calculation of change needs two assessments
(baseline and endpoint) that can be difficult to obtain in unsta-
ble and difficult-to-measure conditions such as schizophrenia. We
have decided primarily to use endpoint data, and only use change
data if the former are not available. If necessary, we will com-
bine endpoint and change data in the analysis, as we prefer to use
mean differences (MDs) rather than standardised mean differences
(SMDs) throughout (Deeks 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we will apply the following standards
to relevant continuous data before inclusion.
For endpoint data from studies including fewer than 200 partici-
pants:
1. when a scale starts from the nite number zero, we will
subtract the lowest possible value from the mean, and divide this
by the standard deviation (SD). If this value is lower than one, it
strongly suggests that the data are skewed and we will exclude
these data. If this ratio is higher than one but less than two, there
is suggestion that the data are skewed: we will enter these data
and test whether their inclusion or exclusion would change the
results substantially. If such data change results we will enter as
‘other data’. Finally, if the ratio is larger than two we will include
these data, because it is less likely that they are skewed (Altman
1996).
2. if a scale starts from a positive value (such as the PANSS,
which can have values from 30 to 210 (Kay 1986)), we will
modify the calculation described above to take the scale starting
point into account. In these cases skewed data are present if 2 SD
> (S − S min), where S is the mean score and ‘S min’ is the
minimum score.
Please note that we will enter all relevant data from studies of more
than 200 participants in the analysis irrespective of the above rules,
because skewed data pose less of a problem in large studies. We will
also enter all relevant change data, as when continuous data are
presented on a scale that includes a possibility of negative values
(such as change data), it is difficult to tell whether or not data are
skewed.
2.5 Common measurement
To facilitate comparison between trials we aim, where relevant, to
convert variables that can be reported in different metrics, such as
days in hospital (mean days per year, per week or per month) to a
common metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we will make efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
‘clinically improved’ or ‘not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the BPRS (Overall 1962), or the PANSS (Kay 1986), this
could be considered as a clinically significant response (Leucht
2005a; Leucht 2005b). If data based on these thresholds are not
available, we will use the primary cut-off presented by the study
authors.
2.7 Direction of graphs
Where possible, we will enter data in such a way that the area to the
left of the line of no effect indicates a favourable outcome for high
dosage quetiapine. Where keeping to this makes it impossible to
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avoid outcome titles with clumsy double-negatives (e.g. ‘not un-
improved’) we will report data where the left of the line indicates
an unfavourable outcome and note this in the relevant graphs.
Assessment of risk of bias in included studies
Review authors YI, CC, MW and HE will independently assess
risk of bias using criteria described in the Cochrane Handbook for
Systematic Reviews of Interventions to assess trial quality (Higgins
2011a). This set of criteria is based on evidence of associations
between potential overestimation of effect and the level of risk of
bias of the article that may be due to aspects of sequence genera-
tion, allocation concealment, blinding, incomplete outcome data
and selective reporting, or the way in which these ‘domains’ are
reported.
If the review authors disagree, we will make the final rating by
consensus. Where inadequate details of randomisation and other
characteristics of trials are provided, we will attempt to contact
study authors to obtain further information. We will report non-
concurrence in quality assessment, but if disputes arise regarding
the category to which a trial is to be allocated, we will resolve this
by discussion.
We will note the level of risk of bias in the review text, Risk of bias
tables, and the ‘Summary of findings’ table(s).
Measures of treatment effect
1. Binary data
For binary outcomes we will calculate a standard estimation of
the risk ratio (RR) and its 95% confidence interval (CI), as it
has been shown that RR is more intuitive than odds ratios (OR)
(Boissel 1999); and that OR tend to be interpreted as RR by
clinicians (Deeks 2000). Although the number needed to treat for
an additional beneficial outcome (NNTB) and the number needed
to treat for an additional harmful outcome (NNTH), with their
CIs, are intuitively attractive to clinicians, they are problematic
to calculate and interpret in meta-analyses (Hutton 2009). For
binary data presented in the ‘Summary of findings’ table(s) we
will, where possible, calculate illustrative comparative risks.
2. Continuous data
For continuous outcomes we will estimate MD between groups.
We prefer not to calculate effect size measures (SMD). However
if trials use scales of very considerable similarity, we will presume
there is a small difference in measurement, and we will calculate
effect size and transform the effect back to the units of one or more
of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ‘cluster randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Study authors often fail to account
for intra-class correlation in clustered studies, leading to a unit-
of-analysis error whereby P values are spuriously low, CIs unduly
narrow and statistical significance overestimated (Divine 1992).
This causes type I errors (Bland 1997; Gulliford 1999).
Where clustering has been incorporated into the analysis of pri-
mary studies, we will present these data as if from a non-cluster
randomised study, but adjust for the clustering effect.
Where clustering is not accounted for in primary studies, we will
present data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. We will seek to contact the
first authors of studies to obtain intra-class correlation coefficient
(ICC) values for their clustered data and to adjust for this by using
accepted methods (Gulliford 1999).
We have sought statistical advice and have been advised that the
binary data from cluster trials presented in a report should be
divided by a ‘design effect’. This is calculated using the mean
number of participants per cluster (m) and the ICC: thus design
effect = 1 + (m − 1) * ICC (Donner 2002). If the ICC is not
reported we will assume it to be 0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed and taken ICCs
and relevant data documented in the report into account, synthesis
with other studies will be possible using the generic inverse variance
technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. This
occurs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the sec-
ond phase. As a consequence, participants can differ significantly
from their initial state at entry to the second phase, despite a wash-
out phase. For the same reason cross-over trials are not appropriate
if the condition of interest is unstable (Elbourne 2002). As both
carry-over and unstable conditions are very likely in severe men-
tal illness, we will only use data from the first phase of cross-over
studies.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant,
we will present the additional treatment arms in comparisons. If
data are binary, we will add these and combine within the two-
by-two table. If data are continuous, we will combine data follow-
ing the formula provided in the Cochrane Handbook for Systematic
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Reviews of Interventions (Higgins 2011b). Where additional treat-
ment arms are irrelevant to this review, we will not reproduce these
data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We choose that, for any particular outcome, should more
than 50% of data be unaccounted for we will not reproduce these
data or use them within analyses. If, however, more than 50% of
those in one arm of a study are lost, but the total loss is less than
50%, we will address this within the ‘Summary of findings’ table(s)
by downgrading the certainty of the evidence. Finally, we will also
downgrade the certainty of the evidence within the ‘Summary of
findings’ table(s) should the loss be 25% to 50% in total.
2. Binary
In the case where attrition for a binary outcome is between 0%
and 50% and where these data are not clearly described, we will
present data on a ‘once-randomised-always-analyse’ basis (an in-
tention-to-treat (ITT) analysis). Those leaving the study early are
all assumed to have the same rates of negative outcome as those
who completed. We will use the rate of those who stay in the study
- in that particular arm of the trial - and apply this also to those
who did not. We will undertake a sensitivity analysis testing how
prone the primary outcomes are to change when data only from
people who complete the study to that point are compared to the
ITT analysis using the above assumptions.
3. Continuous
3.1 Attrition
We will use data where attrition for a continuous outcome is be-
tween 0% and 50%, and data only from participants who com-
plete the study to that point are reported.
3.2 Standard deviations
If SDs are not reported, we will try to obtain the missing values
from the study authors. If these are not available, where there are
missing measures of variance for continuous data, but an exact
standard error (SE) and CIs available for group means, and either
P value or t value available for differences in mean, we can calculate
SDs according to the rules described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b). When only
the SE is reported, SDs are calculated by the formula SD = SE *
√
(n). The Cochrane Handbook for Systematic Reviews of Interven-
tions presents detailed formulae for estimating SDs from P, t or
F values, CIs, ranges or other statistics (Higgins 2011b). If these
formulae do not apply, we will calculate the SDs according to a
validated imputation method, which is based on the SDs of the
other included studies (Furukawa 2006). Although some of these
imputation strategies can introduce error, the alternative would be
to exclude a given study’s outcome and thus to lose information.
Nevertheless, we will examine the validity of the imputations in a
sensitivity analysis that excludes imputed values.
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
the trials early or were lost to follow-up. Some trials just present
the results of study completers; others use the method of last ob-
servation carried forward (LOCF); while more recently, methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM) have become more of a standard. While
the latter methods seem to be somewhat better than LOCF (Leon
2006), we feel that the high percentage of participants leaving the
studies early and differences between groups in their reasons for
doing so is often the core problem in randomised schizophrenia
trials. We will therefore not exclude studies based on the statistical
approach used. However, by preference we will use the more so-
phisticated approaches, i.e. we will prefer to use MMRM or mul-
tiple-imputation to LOCF, and we will only present completer
analyses if some kind of ITT data are not available at all. Moreover,
we will address this issue in the item ‘Incomplete outcome data’
of the ‘Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
We will consider all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We will simply in-
spect all studies for participants who are clearly outliers or situ-
ations that we had not predicted would arise and, where found,
discuss such situations or participant groups.
2. Methodological heterogeneity
We will consider all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We will sim-
ply inspect all studies for clearly outlying methods which we had
not predicted would arise and discuss any such methodological
outliers.
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3. Statistical heterogeneity
3.1 Visual inspection
We will inspect graphs visually to investigate the possibility of
statistical heterogeneity.
3.2 Employing the I² statistic
We will investigate heterogeneity between studies by considering
the I² statistic alongside the Chi² P value. The I² statistic provides
an estimate of the percentage of inconsistency thought to be due
to chance (Higgins 2003). The importance of the observed value
of I² statistic depends on the magnitude and direction of effects as
well as the strength of evidence for heterogeneity (e.g. P value from
Chi² test, or a confidence interval for I² statistic). We will interpret
an I² estimate greater than or equal to 50% and accompanied by
a statistically significant Chi² statistic as evidence of substantial
heterogeneity (Deeks 2011). When substantial levels of hetero-
geneity are found in the primary outcome, we will explore reasons
for heterogeneity (see the Subgroup analysis and investigation of
heterogeneity section).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10.1 of the Cochrane Handbook for
Systemic reviews of Interventions (Sterne 2011).
1. Protocol versus full study
We will try to locate protocols of included randomised trials. If the
protocol is available, we will compare outcomes in the protocol
and in the published report . If the protocol is not available, we
will compare outcomes listed in the methods section of the trial
report with actually reported results.
2. Funnel plot
We are aware that funnel plots may be useful in investigating
reporting biases but are of limited power to detect small-study
effects. We will not use funnel plots for outcomes where there are
ten or fewer studies, or where all studies are of similar size. In other
cases, where funnel plots are possible, we will seek statistical advice
in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies, even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model: it puts added weight onto small studies,
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
With this in mind, we will use a fixed-effect model for all analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
We do not anticipate performing subgroup analysis, considering
limited available evidence of quetiapine dosage in schizophrenia.
If data are available we will, for primary outcomes, perform a
subgroup analysis to test if dose of quetiapine has different effects
for adolescents (16 to 18 years) compared with adults (over 18
years).
2. Investigation of heterogeneity
We will report if inconsistency is high. Firstly, we will investigate
whether data have been entered correctly. Secondly, if data are cor-
rect, we will inspect the graph visually and remove outlying studies
successively to see if homogeneity is restored. For this review we
have decided that should this occur with data contributing to the
summary finding of no more than 10% of the total weighting,
we will present data. If not, we will not pool these data and will
discuss any issues. We know of no supporting research for this
10% cut-off but are investigating use of prediction intervals as an
alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity is
obvious, we will simply state hypotheses regarding these for future
reviews or versions of this review. We do not anticipate undertaking
analyses relating to these.
Sensitivity analysis
If there are substantial differences in the direction or precision of
effect estimates in the sensitivity analyses listed below, we will not
add data from the lower-quality studies to the results of the higher-
quality trials, but will present these data within a subcategory. If
their inclusion does not result in a substantive difference, they will
remain in the analyses.
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1. Implication of randomisation
If trials are described in some way as to imply randomisation, for
the primary outcomes, we will pool data from the implied trials
with trials that are randomised.
2. Assumptions for lost binary data
Where assumptions have to be made regarding people lost to fol-
low-up (see Dealing with missing data) we will compare the find-
ings of the primary outcomes when we use our assumption com-
pared with completer data only. If there is a substantial difference,
we will report results and discuss them but continue to employ
our assumption.
Where assumptions have to be made regarding missing SDs (see
Dealing with missing data), we will compare the findings on pri-
mary outcomes when we use our assumption compared with com-
pleter data only. We will undertake a sensitivity analysis testing
how prone results are to change when ‘completer’ data only are
compared to the imputed data using the above assumption. If there
is a substantial difference, we will report results and discuss them
but continue to employ our assumption.
3. Risk of bias
We will analyse the effects of excluding trials that are at high risk
of bias across one or more of the domains (see Assessment of risk
of bias in included studies) for the meta-analysis of the primary
outcome.
4. Imputed values
We will also undertake a sensitivity analysis to assess the effects of
including data from trials where we use imputed values for ICC
in calculating the design effect in cluster-randomised trials.
5. Fixed- and random-effects
We will synthesise data using a fixed-effect model taking into the
account the relative advantages and disadvantages of a fixed-effect
versus random-effect. However, we will also synthesise data for
the primary outcome using the random-effects model to evaluate
whether this alters the significance of the results.
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